Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-08-16
2011-08-16
Gambel, Phillip (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S387300, C530S387900, C530S388200, C424S130100, C424S133100, C424S139100, C424S145100, C424S158100
Reexamination Certificate
active
07999081
ABSTRACT:
The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterised by the ability to inhibit the conversion of the C5 alpha chain to C5aand C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system.
REFERENCES:
patent: 5770429 (1998-06-01), Lonberg et al.
patent: 6355245 (2002-03-01), Evans et al.
patent: 2003/0039649 (2003-02-01), Foote
patent: 2004/0001822 (2004-01-01), Levanon et al.
patent: WO 02/30985 (2002-04-01), None
Rudikoff et al., Proc Natl Acad Sci USA 79: 1979-1983, 1982.
Colman, Research in Immunology 145: 33-36, 1994.
Kussie et al., J. Immunol. 152: 146-152, 1994.
Chen et al., EMBO J., 14: 2784-2794, 1995.
Lederman et al., Molecular Immunology 28: 1171-1181, 1991.
Li et al., PNAS 77: 3211-3214, 1980.
Evans et al., “In Vitro and In Vivo Inhibition of Complement Activity by a Single-Chain Fv Fragment Recognizing Human C5.” Mol. Immunol. 32:1183-1195, 1995.
Fitch et al., “Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery with Cardiopulmonary Bypass,” Circulation 100:2499-2506, 1999.
Thomas et al., “Inhibition of Complement Activity by Humanized Anti-C5 Antibody and Single-Chain Fv,” Mol. Immunol. 33:1389-1401, 1996.
Wang et al., “Amelioration of Lupus-like Autoimmune Disease in NZB/W F1 Mice After Treatment with a Blocking Monoclonal Antibody Specific for Complement Component C5,” Proc. Natl. Acad. Sci. U.S.A. 93:8563-8568, 1996.
Bui, H.H., et al., “Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines,”BMC Bioinformatics8:361, BioMed Central Ltd., England (Sep. 2007).
Collet, X., et al., “Evolution of mammalian apolipoprotein A-I and conservation of antigenicity: correlation with primary and secondary structure,”J. Lipid Res.38(4):634-44, American Society for Biochemistry and Molecular Biology, United States (Apr. 1997).
Fredslund, F., et al., “Structure of and influence of a tick complement inhibitor on human complement component 5,”Nat. Immunol.9(7):753-60, Nature Publishing Group, United States (Jul. 2008; Epub: Jun. 2008).
Jemmerson, R., et al., “Analysis of an evolutionarily conserved antigenic site on mammalian cytochromecusing synthetic peptides,”Proc. Natl. Acad. Sci. USA82(5):1508-12, National Academy of Sciences, United States (Mar. 1985).
Marzari, R., et al., “The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies,”Eur. J. Immunol.32(10):2773-82, Wiley-VCH Verlag GmbH & Co., Germany (Oct. 2002).
Potter, N. T., et al., “Identification of an antigenic determinant within the phylogenetically conserved triprolyl region of myelin basic protein,”J. Immunol.136(2):516-20, The American Association of Immunologists, United States (Jan. 1986).
Sandoval, A., et al., “Distal recognition site for classical pathway convertase located in the C345C
etrin module of complement component C5,”J. Immunol.165(2):1066-73, The American Association of Immunologists, United States (Jul. 2000).
Marzari Roberto
Tedesco Francesco
Adienne SRL
Gambel Phillip
Sterne, Kessler, Goldstein & Fox P.L.LC.
LandOfFree
Anti-C5 alpha antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-C5 alpha antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-C5 alpha antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2782115